Dear Jhinvestor51. I believe in you when you write as a
Dear Jhinvestor51. I believe in you when you write as a "GTRQlonger". I am also in the same boat from Long. I bought 40.000 shares at 0.15 (6.000 US$) when A/S was I think was 75 Million Shares now I think it is 300 Million shares (4X) but O/S keeps quite the same numbers.
As GTRQ longers we both are, we must understand that we have lost almost all our value as in my case from 6.000 US$ now I am not sure if that could be sold at 96 US$ or 280 US$.
If I sell my 40.000 shares 96/280 US$ then I have to be sure GTRQ is loose from all lost. Is a dead fish. I can't say that. I have not the data to say that. If I sell now I will give also to be lost not only more than 95% of my investment, also more than 3 years waiting.
Your situation might be even better than mine
Sell to longers is not an option
I can't understand the 0.0024/0.0026 price to sell. I can't see what kind of sellers this such low price can be a reasonable option.
There is a case of some shareholder with almost 500.000 thousand shares bought before this was GEOTRAQ and he bought those for just nothing. Maybe there are some in the same profile, maybe they get some earnings with 0.0024 sells. Maybe they had lost a part of their faith and are leaking their GTRQ portfolio at these such low prices to the loss for us, but they sell for some earnings.
Are you really willing to sell at these prices, been a longer?
Might be a case, but I can't be sure.
We have no info, nor data to say these project is dead
Salute
Traack Technologies Inc. (TRAA) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...
Continue Reading
New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...
Continue Reading
Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...
Continue Reading
IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...
Continue Reading
Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...
Continue Reading
Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...
Continue Reading
A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...
Continue Reading
A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...
Continue Reading
JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...
Continue Reading
Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...
Continue Reading
Top 5 Most Recently Viewed Articles
Parker Waichman LLP Takes Action Against Drug Manufacturer Parker Waichman, a prominent national law firm, is actively filing lawsuits for individuals who assert that they developed NAION after using Novo Nordisk's medications, Ozempic or Wegovy. The firm recently initiated a case for a Florida resident who experienced this severe eye condition after using Ozempic....
Continue Reading
C.H. Robinson's Upcoming Earnings Release and Conference Call C.H. Robinson Worldwide, Inc. (Nasdaq: CHRW), a leading logistics provider, has announced significant plans for its upcoming earnings release. The company is scheduled to share its third quarter 2024 results post market close. On this important day, the company will hold a conference call to delve into the...
Continue Reading
PayPal's Innovative Partnership with OpenAI Shares of PayPal Holdings Inc (NASDAQ: PYPL) experienced a notable increase of 14.38% in pre-market trading. This rise was sparked by the recent announcement of a deal between the payments giant and OpenAI. This partnership focuses on integrating PayPal's digital wallet into the popular AI platform, ChatGPT. Enabling...
Continue Reading
Introduction to the Partnership In an exciting development, Uber Technologies Inc (NYSE: UBER) has announced a strategic partnership with Nvidia Corp (NASDAQ: NVDA) aimed at leveraging artificial intelligence (AI) to enhance ridesharing and autonomous vehicle technology. Analyst Justin Post from BofA Securities has enthusiastically maintained a Buy rating on Uber’s...
Continue Reading
Overview of Organic Infant Formula Market Growth The Organic Infant Formula market has seen remarkable expansion, indicating a shift in parental preferences towards health-conscious choices for their young ones. The market, which had a valuation of USD 20.8 billion in the recent past, is expected to reach an impressive USD 36.04 billion by 2032. This growth trajectory...
Continue Reading